Literature DB >> 12871409

A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis.

M J A Simmelink1, P G De Groot, R H W M Derksen.   

Abstract

Anti-prothrombin antibodies are a frequent cause of lupus anticoagulant (LAC), a thrombotic risk factor. Prothrombin shares structural homology with plasminogen, a kringle protein with an important role in fibrinolysis. Cross-reactivity between antiprothrombin antibodies and plasminogen has been described. To study associations between LAC, IgG and IgM class antiprothrombin and antiplasminogen antibodies, plasminogen activity levels and thrombosis in selected patients with systemic autoimmune diseases. Patients included forty-six consecutive LAC-positive patients (29 with systemic lupus erythematosus (SLE); 33 with a thrombotic history), 38 patients without LAC (36 with SLE; seven with a history of thrombosis) and 40 healthy controls. In the total group of 84 patient samples, the prevalence of antiprothrombin and antiplasminogen antibodies was 30 and 38%, respectively. There was no significant relationship between the presence of these antibodies. In contrast to presence of antiplasminogen antibodies, presence of antiprothrombin antibodies was statistically significant related to thrombosis. Thirteen samples had antiprothrombin and antiplasminogen antibodies of similar isotype (IgG, n= 4; IgM, n= 9). Of these, all but one had LAC and 11/13 came from patients with a history of thrombosis. Simultaneous presence of IgM-class antiprothrombin and antiplasminogen antibodies had a significant association with thrombosis. Levels of plasminogen activity were similar in samples from healthy controls and patients (with or without antiplasminogen antibodies or thrombosis). Anti-prothrombin antibodies and antiplasminogen antibodies occur frequently in patients with systemic autoimmune disease. Anti-prothrombin antibodies, but not antiplasminogen antibodies are a risk factor for thrombosis. Anti-plasminogen are in most cases unrelated to antiprothrombin antibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871409     DOI: 10.1046/j.1538-7836.2003.00137.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  4 in total

1.  Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis.

Authors:  David J Bautz; Gloria A Preston; Sofia Lionaki; Peter Hewins; Alisa S Wolberg; Jia Jin Yang; Susan L Hogan; Hyunsook Chin; Stephan Moll; J Charles Jennette; Ronald J Falk
Journal:  J Am Soc Nephrol       Date:  2008-08-13       Impact factor: 10.121

2.  IgG antibodies to plasminogen and their relationship to IgG anti-beta(2)-glycoprotein 1 antibodies and thrombosis.

Authors:  Chunya Bu; Zhihuan Li; Chune Zhang; Lei Gao; Guoping Cai
Journal:  Clin Rheumatol       Date:  2007-07-24       Impact factor: 2.980

3.  Autoantibodies to plasminogen and tissue plasminogen activator in women with recurrent pregnancy loss.

Authors:  C Bu; C Zhang; Z Li; L Gao; Z Xie; G Cai
Journal:  Clin Exp Immunol       Date:  2007-04-11       Impact factor: 4.330

Review 4.  Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.

Authors:  Pier Luigi Meroni; Cecilia Beatrice Chighizola; Francesca Rovelli; Maria Gerosa
Journal:  Arthritis Res Ther       Date:  2014       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.